IP Library › Granted Patent US 10,590,417
Granted Patent B2
US 10,590,417 · App. 16/152,911 · Granted Mar 17, 2020

RNA ligand-displaying exosomes for specific delivery of therapeutics to cell by RNA nanotechnology

Inventors: Peixuan Guo (Dubin, OH); Fengmei Pi (Columbus, OH); Hui Li (San Francisco, CA); Shaoying Wang (Middlesex, NJ)
Assignee: Ohio State Innovation Foundation
C12N15/113A61K9/1273A61K9/51A61K9/513A61P35/00C12N15/111C12N2310/14C12N2310/51C12N2320/32
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,590,417
App. No.
16/152,911
Granted
Mar 17, 2020
Kind
B2
Abstract

Disclosed herein are compositions comprising extracellular vesicles, such as exosomes, displaying an RNA nanoparticle on its surface. The RNA nanoparticle can target the extracellular vesicle to a given cell via a targeting moiety. The extracellular vesicle can also comprise a functional moiety, which can be used in treatment or diagnostics.

Claims (34)

1. A composition comprising an RNA nanoparticle anchored on the surface of an extracellular vesicle membrane,

wherein the nanoparticle is assembled from one or more ribonucleic acid strands duplexed together to form a secondary structure with three or more projecting stem loops,

wherein at one of the three or more projecting stem loops is conjugated to a cholesterol moiety

wherein at one of the three or more projecting stem loops comprises one or more functional moieties, and

wherein at least one of the three or more projecting stem loops physically blocks encapsulation of the nanoparticle into the extracellular vesicle.

2. The composition of claim 1 , wherein at least one of the three or more ribonucleic acid strands comprise a pRNA-3WJ core.

3. The composition of claim 1 , wherein the RNA nanoparticle is assembled from three ribonucleic acid strands comprising the nucleic acid sequence SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3.

4. The composition of claim 1 , wherein one or more of the functional moieties comprises a targeting moiety.

5. The composition of claim 4 , wherein the targeting moiety directs the exosome to a cell of interest.

6. The composition of claim 4 , wherein the targeting moiety is selected from an RNA aptamer, modified RNA aptamer, DNA aptamer, modified DNA aptamer, and chemical ligand.

7. The composition of claim 1 , wherein one or more of the functional moieties comprises a therapeutic moiety or a diagnostic moiety.

8. The composition of claim 7 , wherein the therapeutic moiety or a diagnostic moiety comprises an RNA aptamer, a ribozyme, siRNA, protein-binding RNA aptamer, or small molecule.

9. The composition of claim 1 , wherein the extracellular vesicle comprises an exosome.

10. A method of targeting an extracellular vesicle to a cell of interest comprising: contacting the cell with a composition comprising an extracellular vesicle displaying an RNA nanoparticle on its surface,

wherein the nanoparticle is assembled from one or more ribonucleic acid strands duplexed together to form a secondary structure with three or more projecting stem loops,

wherein at one of the three or more projecting stem loops is conjugated to a cholesterol moiety,

wherein at least one of the three or more projecting stem loops physically blocks encapsulation of the nanoparticle into the extracellular vesicle, and

wherein at one of the three or more projecting stem loops comprises at least one targeting moiety that directs the extracellular vesicle to the cell of interest.

11. The method of claim 10 , wherein the cell is in a subject.

12. The method of claim 10 , wherein the cell is a cancer cell.

13. The method of claim 10 , wherein the RNA nanoparticle further comprises a functional moiety.

14. A method of treating disease in a subject, comprising administering to the subject composition comprising an extracellular vesicle displaying an RNA nanoparticle on its surface,

wherein the nanoparticle is assembled from one or more ribonucleic acid strands duplexed together to form a secondary structure with three or more projecting stem loops,

wherein at one of the three or more projecting stem loops is conjugated to a cholesterol moiety,

wherein at least one of the three or more projecting stem loops physically blocks encapsulation of the nanoparticle into the extracellular vesicle, and

wherein at one of the three or more projecting stem loops comprises one or more functional moieties capable of treating the disease in the subject.

15. The method of claim 14 , wherein the disease is an infection.

16. The method of claim 14 , wherein the disease is cancer.

17. A method of imaging a cell, the method comprising contacting the cell with a composition comprising an extracellular vesicle displaying an RNA nanoparticle on its surface,

wherein the nanoparticle is assembled from one or more ribonucleic acid strands duplexed together to form a secondary structure with three or more projecting stem loops,

wherein at one of the three or more projecting stem loops is conjugated to a cholesterol moiety

wherein at least one of the three or more projecting stem loops physically blocks encapsulation of the nanoparticle into the extracellular vesicle, and

wherein at one of the three or more projecting stem loops comprises one or more diagnostic moieties.

18. The method of claim 17 , wherein the cell is in a subject.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 6, 2019
From: GUO, PEIXUAN; PI, FENGMEI; LI, HUI; WANG, SHAOYING
To: OHIO STATE INNOVATION FOUNDATION
Reel/Frame 050931/0141 →
Continuity (4)
Continuation PCTUS2017026165 · Apr 5, 2017
Provisional Application 62319104 · Apr 6, 2016
Provisional Application 62380233 · Aug 26, 2016
Related Publication 20190024085A1 · Jan 24, 2019
Cited By (1)
US 12,441,997